Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)

NCT01659255 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01659255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01659255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
August 17, 2012
Completion date
January 11, 2016
Enrollment
90 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia, non hodgkins lymphoma